Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dbv Technologies ADR (NQ: DBVT )

1.990 +0.030 (+1.53%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 48,725
Open 1.960
Bid (Size) 1.810 (1)
Ask (Size) 2.120 (11)
Prev. Close 1.960
Today's Range 1.930 - 2.010
52wk Range 1.080 - 3.430
Shares Outstanding 55,096,537
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers NeoGames S.A. (NASDAQ: NGMS) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash. 
Via Benzinga

Performance

YTD
+32.67%
+32.67%
1 Month
+27.56%
+27.56%
3 Month
+38.19%
+38.19%
6 Month
+49.62%
+49.62%
1 Year
+26.75%
+26.75%

More News

Read More
Why Shares of DBV Technologies Jumped Thursday
Via The Motley Fool
Earnings Preview: DBV Technologies
Via Benzinga
Good News For Toddlers With Peanut Allergy: DBVT Data Shows Promising Results for Peanut Allergy Patch
Via Benzinga
DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin™ Peanut in Toddlers
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies to Participate in Upcoming Investor Conference
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies Reports First Quarter 2023 Financial Results
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies Outlines Regulatory Path For Viaskin Peanut Allergy Patch For Kids Below 3 Years
Via Benzinga
DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDA
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General Meeting
From DBV Technologies S.A.
Via GlobeNewswire
7 Penny Stocks Sitting in the Sweet Spot
Via InvestorPlace
Ordinary and Extraordinary General Meeting of April 12, 2023
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies Update
From DBV Technologies S.A.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
DBV Technologies Announces First Patient Screened in VITESSE Phase 3 Clinical Trial in Peanut-Allergic Children 4 – 7 Years Old
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies announces filing of 2022 Annual Report on Form 10-K and 2022 Universal Registration Document
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies Reports Full Year 2022 Financial Results and Business Update
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies to Report Full Year 2022 Financial Results and Business Updates on March 2, 2023
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies to Participate in Upcoming AAAAI 2023 Congress
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies to Participate in Upcoming Investor Conference
From DBV Technologies S.A.
Via GlobeNewswire
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
From DBV Technologies S.A.
Via GlobeNewswire
Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2022
From DBV Technologies S.A.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.